Report Overview:
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer
This report provides a deep insight into the global CAR T-cell Therapy Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porters five forces analysis, value chain analysis, etc.
Market Value:
The Global CAR T-cell Therapy Drug Market Size was estimated at USD 585.21 million in 2024 and is projected to reach USD 2811.7 million by 2030, exhibiting a CAGR of 29.90% during the forecast period. CAGR of 29.90%
(2022 – 2029)
By Types:
• CD19-targeted
• BCMA-targeted
